Be Biopharma is focused on developing innovative B cell therapies aimed at transforming treatment for serious diseases, particularly hemophilia B. The company is pioneering engineered B cell medicines, which leverage the therapeutic potential of these cells to create advanced protein-based therapies. This approach is designed to enhance patient outcomes by providing more effective and targeted treatment options, thereby addressing the unmet needs of individuals living with complex health conditions.

The company emphasizes a patient-centered mission, ensuring that their scientific advancements are aligned with the needs and experiences of those they serve. By reimagining traditional therapies, Be Biopharma aims to offer greater freedom and improved quality of life for patients. Their commitment to advancing science with a focus on humanity underscores their dedication to not only innovation but also to the well-being of patients and caregivers involved in the treatment process.

United States

Be Bio is pioneering Engineered B Cell Medicines (BCMs) to dramatically improve the lives of patients who are living with Hemophilia B and other genetic diseases, cancer, and other serious conditions. With eyes locked on the patient, our team of purpose-driven scientists, technologists, manufacturing experts and business builders collaborate to create a bold new class of cell therapies.

Be Biopharma

Company Details